Open access
Open access
Powered by Google Translator Translator

Oncology – Brain

SR | Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation

19 Jan, 2023 | 14:09h | UTC

Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

Summary: Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation – Cochrane Library

 


Cohort Study | Brain cancer after radiation exposure from CT examinations of children and young adults

18 Jan, 2023 | 14:36h | UTC

Brain cancer after radiation exposure from CT examinations of children and young adults: results from the EPI-CT cohort study – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Large Multinational Study Shows Link Between CT Radiation Exposure and Brain Cancer in Children and Young Adults – Diagnostic Imaging

New cancer risk analysis prompts experts to call for ‘careful justification’ of pediatric head CTs – Health Imaging

CT brain cancer risk quantified for children and young adults – medwire News

 


NCCN Guideline | Pediatric central nervous system cancers

12 Jan, 2023 | 13:11h | UTC

Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Editorial: ASCO Living Guidelines: The Next Frontier

 


Single-arm phase 1b study | Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma.

11 Nov, 2022 | 13:00h | UTC

Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial – The Lancet Oncology (link to abstract – $ for full-text)

 


Phase 2 RCT | Concurrent Bevacizumab and reirradiation vs. Bevacizumab alone as treatment for recurrent glioblastoma.

9 Nov, 2022 | 12:21h | UTC

NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Bevacizumab Plus Reirradiation Improves PFS in Glioblastoma Multiforme – OncLive

 


Post-trial follow-up | Long-term outcomes with stereotactic radiosurgery vs. whole-brain RT for resected brain metastasis.

7 Nov, 2022 | 12:22h | UTC

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

Commentary: Survivors face less late cognitive deterioration after stereotactic radiosurgery than WBRT – medwire News

Original Study: Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Isocitrate dehydrogenase mutant gliomas: consensus review on diagnosis, management, and future directions.

17 Oct, 2022 | 12:31h | UTC

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions – Neuro-Oncology

 


M-A | Extent of tumor resection and survival in pediatric patients with high-grade gliomas.

17 Aug, 2022 | 14:00h | UTC

Extent of Tumor Resection and Survival in Pediatric Patients With High-Grade Gliomas: A Systematic Review and Meta-analysis – JAMA Network Open

 

Commentary on Twitter

 


ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.

29 Jul, 2022 | 12:33h | UTC

Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline – Practical Radiation Oncology

 


Single-arm study | Intensive multimodality therapy for extraocular retinoblastoma.

21 Jul, 2022 | 12:25h | UTC

Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children’s Oncology Group Trial (ARET0321) – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


The Global Retinoblastoma Outcome Study | A prospective, cluster-based analysis of 4,064 patients from 149 countries.

14 Jul, 2022 | 12:16h | UTC

The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries – The Lancet Global Health

Invited Commentary: Retinoblastoma as a lens for correctable disparities worldwide – The Lancet Global Health

News Release: Children in low-income countries 16 times more likely to die from most common eye cancer – London School of Hygiene & Tropical Medicine

 


Phase II RCT | Proton craniospinal irradiation vs. photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis.

13 Jul, 2022 | 11:09h | UTC

Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Phase 1 single-arm study | Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma.

4 Jul, 2022 | 12:08h | UTC

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Oncolytic Virus Infusion Promising as Brain-Stem Glioma Treatment — Phase I trial shows encouraging OS in children with diffuse intrinsic pontine glioma – MedPage Today (free registration required)


Joint final report of Phase III trials demonstrate positive outcomes from combination of PCV chemotherapy and RT in patients with anaplastic oligodendroglial tumors.

30 Jun, 2022 | 10:16h | UTC

News Release: Joint final report of Phase III trials demonstrate positive outcomes from combination of PCV chemotherapy and RT in patients with anaplastic oligodendroglial tumors – NPR Oncology

Original Study: Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors – Journal of Clinical Oncology

 


M-A: Stereotactic radiosurgery vs. whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer.

30 May, 2022 | 10:41h | UTC

Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis – The Lancet Oncology (link to abstract – $ for full-text)

News Release: Meta-Analysis Shows Targeted Radiation Therapy May Be as Effective as Standard Care for Small Cell Lung Cancer Patients with Brain Metastases – St. Michael’s Hospital

 


Cohort Study: Effect of awake craniotomy in glioblastoma in eloquent areas.

23 May, 2022 | 00:40h | UTC

Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study – the Lancet Oncology (link to abstract – $ for full-text)

Commentary: Neurologic and Survival Outcomes After Awake Craniotomy for Glioblastoma – The ASCO Post

 

Commentary on Twitter

 


RCT: Treatment with Etirinotecan pegol for patients with metastatic breast cancer and brain metastases.

13 May, 2022 | 10:51h | UTC

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial – JAMA Oncology (free for a limited period)

 

Commentary on Twitter

 


ASTRO Guideline: Radiation therapy for brain metastases.

12 May, 2022 | 10:11h | UTC

Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline – Practical Radiation Oncology

News Release: ASTRO issues clinical guideline on radiation therapy for brain metastases – American Society for Radiation Oncology

 

Commentary on Twitter

 


Study finds no increased risk of brain tumors for mobile phone users.

1 Apr, 2022 | 10:04h | UTC

News Release: No increased risk of brain tumours for mobile phone users, new study finds – University of Oxford

Original Study: Cellular Telephone Use and the Risk of Brain Tumors: Update of the UK Million Women Study – JNCI: Journal of the National Cancer Institute

 


SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases.

18 Mar, 2022 | 08:14h | UTC

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021) – Clinical and Translational Oncology

 


Same-day discharge after brain tumor resection: a prospective pilot study.

9 Mar, 2022 | 08:19h | UTC

Same-day discharge after brain tumor resection: a prospective pilot study – Journal of Neuro-Oncology

 

Commentary on Twitter

 


Systematic Review: Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

8 Mar, 2022 | 08:24h | UTC

Diagnostic test accuracy and cost‐effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma – Cochrane Library

 


ASCO-SNO Guideline: Therapy for diffuse astrocytic and oligodendroglial tumors in adults.

26 Jan, 2022 | 01:19h | UTC

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline – Journal of Clinical Oncology

 


Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.

21 Jan, 2022 | 09:36h | UTC

Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline – Journal of Clinical Oncology

Related: EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors.

 


Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.

16 Nov, 2021 | 08:14h | UTC

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases – The University of Texas MD Anderson Cancer Center

Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases

Related: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 


Stay Updated in Your Specialty

No spam, just news.